SI3115372T1 - Tarčni terapevtski fuzijski proteini lizosomalnega encima in njihove uporabe - Google Patents
Tarčni terapevtski fuzijski proteini lizosomalnega encima in njihove uporabeInfo
- Publication number
- SI3115372T1 SI3115372T1 SI201331450T SI201331450T SI3115372T1 SI 3115372 T1 SI3115372 T1 SI 3115372T1 SI 201331450 T SI201331450 T SI 201331450T SI 201331450 T SI201331450 T SI 201331450T SI 3115372 T1 SI3115372 T1 SI 3115372T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fusion proteins
- lysosomal enzyme
- targeted therapeutic
- enzyme fusion
- therapeutic lysosomal
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002132 lysosomal effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730378P | 2012-11-27 | 2012-11-27 | |
| US201361788968P | 2013-03-15 | 2013-03-15 | |
| EP16182420.6A EP3115372B1 (en) | 2012-11-27 | 2013-11-27 | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3115372T1 true SI3115372T1 (sl) | 2019-08-30 |
Family
ID=49753532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331450T SI3115372T1 (sl) | 2012-11-27 | 2013-11-27 | Tarčni terapevtski fuzijski proteini lizosomalnega encima in njihove uporabe |
Country Status (26)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2723412A1 (en) * | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| HUE043679T2 (hu) | 2012-11-27 | 2019-09-30 | Biomarin Pharm Inc | Célra irányított terápiás lizoszomális enzim fúziós fehérjék és alkalmazásaik |
| CA3209821A1 (en) | 2013-05-15 | 2014-11-20 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| US10722559B2 (en) | 2014-08-11 | 2020-07-28 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| WO2016049510A2 (en) * | 2014-09-25 | 2016-03-31 | The General Hospital Corporation | Cell-based targeted delivery of pseudonomas exotoxin |
| WO2016065319A1 (en) * | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| TWI752907B (zh) | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| AU2016349528A1 (en) | 2015-11-06 | 2018-05-17 | Biomarin Pharmaceutical Inc. | Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes |
| US11345904B2 (en) | 2016-02-24 | 2022-05-31 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
| CA3019427A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| CL2016003282A1 (es) | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| JP7348844B2 (ja) | 2017-06-07 | 2023-09-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 内部移行酵素のための組成物および方法 |
| JP7449223B2 (ja) | 2017-09-22 | 2024-03-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ｉｉ型を治療するための遺伝子療法 |
| EP3692070A1 (en) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| MA54792A (fr) * | 2018-03-09 | 2021-12-01 | Avrobio Inc | Compositions et méthodes pour le traitement de la maladie de parkinson |
| WO2019213180A1 (en) | 2018-04-30 | 2019-11-07 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
| US12252544B2 (en) | 2018-05-17 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
| WO2019233842A1 (en) | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| US20220133906A1 (en) * | 2018-11-16 | 2022-05-05 | Asklepios Biopharmaceutical, Inc. | Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal teargeting sequence |
| EP4041284A4 (en) * | 2019-10-10 | 2023-10-18 | Amicus Therapeutics, Inc. | VARIANT OF IGF2 CONSTRUCTS |
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| WO2021183895A1 (en) | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| CN117999278A (zh) | 2021-06-21 | 2024-05-07 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| US20240279360A1 (en) | 2021-06-23 | 2024-08-22 | Lycia Therapeutics, Inc. | Bifunctional compounds containing igf-2 polypeptides |
| CN115975039A (zh) * | 2021-10-15 | 2023-04-18 | 中山大学 | 重组融合抗体和抗体-药物偶联物及其用途 |
| WO2024159071A1 (en) * | 2023-01-27 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| DE10035433C2 (de) | 2000-07-20 | 2002-07-18 | Tuma Wolfgang | Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben |
| WO2002087510A2 (en) * | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| IL161352A0 (en) | 2001-10-16 | 2004-09-27 | Symbiontics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| CA2487815A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050244400A1 (en) * | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| CN101171263A (zh) | 2005-03-04 | 2008-04-30 | 比奥根艾迪克Ma公司 | 通过合理修饰互补决定区残基使免疫球蛋白可变区人源化的方法 |
| CA2723412A1 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
| US9029530B2 (en) | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
| WO2010148253A2 (en) | 2009-06-17 | 2010-12-23 | Zystor Therapeutics, Inc. | Formulations for lysosomal enzymes |
| EP2585385B1 (en) | 2010-06-25 | 2019-12-18 | Amcor Rigid Plastics USA, LLC | Oxygen scavenging system for a container |
| NZ702801A (en) * | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| US9409950B2 (en) * | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| WO2012122042A2 (en) * | 2011-03-04 | 2012-09-13 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| WO2012122477A1 (en) * | 2011-03-10 | 2012-09-13 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| HUE043679T2 (hu) | 2012-11-27 | 2019-09-30 | Biomarin Pharm Inc | Célra irányított terápiás lizoszomális enzim fúziós fehérjék és alkalmazásaik |
-
2013
- 2013-11-27 HU HUE16182420A patent/HUE043679T2/hu unknown
- 2013-11-27 LT LTEP16182420.6T patent/LT3115372T/lt unknown
- 2013-11-27 DK DK16182420.6T patent/DK3115372T3/da active
- 2013-11-27 PL PL13802834T patent/PL2925776T3/pl unknown
- 2013-11-27 HR HRP20181351TT patent/HRP20181351T1/hr unknown
- 2013-11-27 EP EP13802834.5A patent/EP2925776B1/en active Active
- 2013-11-27 CA CA2892146A patent/CA2892146A1/en active Pending
- 2013-11-27 CN CN201380061935.4A patent/CN104822701B/zh active Active
- 2013-11-27 AR ARP130104367A patent/AR093626A1/es active IP Right Grant
- 2013-11-27 PT PT138028345T patent/PT2925776T/pt unknown
- 2013-11-27 WO PCT/US2013/072287 patent/WO2014085621A1/en not_active Ceased
- 2013-11-27 MX MX2015006644A patent/MX367024B/es active IP Right Grant
- 2013-11-27 TW TW102143329A patent/TWI626250B/zh active
- 2013-11-27 US US14/092,336 patent/US9376480B2/en active Active
- 2013-11-27 BR BR112015012152-7A patent/BR112015012152B1/pt active IP Right Grant
- 2013-11-27 KR KR1020157017224A patent/KR102262882B1/ko active Active
- 2013-11-27 AU AU2013352184A patent/AU2013352184B2/en active Active
- 2013-11-27 KR KR1020217017007A patent/KR102385392B1/ko active Active
- 2013-11-27 JP JP2015544209A patent/JP6831176B2/ja active Active
- 2013-11-27 RS RS20190585A patent/RS58916B1/sr unknown
- 2013-11-27 HU HUE13802834A patent/HUE039334T2/hu unknown
- 2013-11-27 MX MX2019009191A patent/MX377150B/es active IP Right Grant
- 2013-11-27 ES ES16182420T patent/ES2729997T3/es active Active
- 2013-11-27 DK DK13802834.5T patent/DK2925776T3/en active
- 2013-11-27 ES ES13802834.5T patent/ES2679374T3/es active Active
- 2013-11-27 KR KR1020237012007A patent/KR20230054482A/ko not_active Ceased
- 2013-11-27 TW TW107114660A patent/TWI711632B/zh active
- 2013-11-27 EP EP16182420.6A patent/EP3115372B1/en active Active
- 2013-11-27 PT PT16182420T patent/PT3115372T/pt unknown
- 2013-11-27 RU RU2015125491A patent/RU2680581C2/ru active
- 2013-11-27 KR KR1020227011416A patent/KR102521039B1/ko active Active
- 2013-11-27 PL PL16182420T patent/PL3115372T3/pl unknown
- 2013-11-27 SI SI201331450T patent/SI3115372T1/sl unknown
-
2015
- 2015-05-14 IL IL238824A patent/IL238824B/en active IP Right Grant
- 2015-05-19 ZA ZA2015/03509A patent/ZA201503509B/en unknown
- 2015-05-20 CL CL2015001371A patent/CL2015001371A1/es unknown
- 2015-10-14 US US14/883,203 patent/US9834588B2/en active Active
- 2015-10-14 US US14/883,211 patent/US9771408B2/en active Active
- 2015-10-14 US US14/883,193 patent/US9834587B2/en active Active
- 2015-10-14 US US14/883,169 patent/US9845346B2/en active Active
-
2017
- 2017-08-28 US US15/688,438 patent/US10301369B2/en active Active
-
2018
- 2018-11-13 IL IL262976A patent/IL262976B/en active IP Right Grant
-
2019
- 2019-04-08 US US16/378,163 patent/US11254725B2/en active Active
- 2019-05-17 HR HRP20190918TT patent/HRP20190918T1/hr unknown
- 2019-06-06 CY CY20191100600T patent/CY1122555T1/el unknown
- 2019-07-24 JP JP2019136013A patent/JP6913719B2/ja active Active
-
2020
- 2020-02-23 IL IL272854A patent/IL272854B/en unknown
-
2022
- 2022-01-10 US US17/572,018 patent/US20220127326A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272854B (en) | Medicinal lysosomal enzyme chimeric proteins and their uses | |
| IL272855A (en) | New and used KIF5B–RET fusion compounds | |
| PT2844667T (pt) | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico | |
| IL236809A0 (en) | Interleukin-10 fusion proteins and their use | |
| PT3744835T (pt) | Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas | |
| IL279676A (en) | Recombinant proteins and therapeutic uses | |
| IL236933A0 (en) | Interleukin-2 fusion proteins and their use | |
| PT3434775T (pt) | Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas | |
| EP2785837A4 (en) | TARGETED ENZYMATIC COMPOUNDS AND ITS USES | |
| IL229753A0 (en) | Proteins that release relaxin and their use | |
| SG11201502455TA (en) | Fgfr3 fusion gene and pharmaceutical drug targeting same | |
| IL222382A0 (en) | Robo1-fc fusion protein and use thereof for treating tumours | |
| EP2880050A4 (en) | NOVEL ENZYMES, ENZYME COMPONENTS AND USES THEREOF | |
| LT2809669T (lt) | Kondensuoti piroldikarboksamidai ir jų panaudojimas kaip vaistų | |
| EP2718432A4 (en) | NUCLEASE FUSION PROTEIN AND USES THEREOF | |
| GB2523211B (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| EP2536741A4 (en) | THERAPY TARGETING FUSIONS OF GENES | |
| AU2012901619A0 (en) | Fusion Proteins and Use Thereof | |
| AU2011902431A0 (en) | Fusion Proteins and Use Thereof | |
| AU2011905077A0 (en) | Radiotracers and Therapeutic Agents |